EP1910524A4 - Modulation der sphingosinkinase-signalgebung - Google Patents

Modulation der sphingosinkinase-signalgebung

Info

Publication number
EP1910524A4
EP1910524A4 EP06752620A EP06752620A EP1910524A4 EP 1910524 A4 EP1910524 A4 EP 1910524A4 EP 06752620 A EP06752620 A EP 06752620A EP 06752620 A EP06752620 A EP 06752620A EP 1910524 A4 EP1910524 A4 EP 1910524A4
Authority
EP
European Patent Office
Prior art keywords
modulation
sphingosine kinase
kinase signalling
signalling
sphingosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06752620A
Other languages
English (en)
French (fr)
Other versions
EP1910524A1 (de
Inventor
Stuart M Pitson
Tamara Leclercq
Mathew Alexander Vadas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medvet Science Pty Ltd
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005903257A external-priority patent/AU2005903257A0/en
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of EP1910524A1 publication Critical patent/EP1910524A1/de
Publication of EP1910524A4 publication Critical patent/EP1910524A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01091—Sphinganine kinase (2.7.1.91)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP06752620A 2005-06-21 2006-06-21 Modulation der sphingosinkinase-signalgebung Withdrawn EP1910524A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005903257A AU2005903257A0 (en) 2005-06-21 A method of modulating enzyme activity and agents for use therein
PCT/AU2006/000866 WO2006135968A1 (en) 2005-06-21 2006-06-21 Modulation of sphingosine kinase signalling

Publications (2)

Publication Number Publication Date
EP1910524A1 EP1910524A1 (de) 2008-04-16
EP1910524A4 true EP1910524A4 (de) 2009-04-01

Family

ID=37570027

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06752620A Withdrawn EP1910524A4 (de) 2005-06-21 2006-06-21 Modulation der sphingosinkinase-signalgebung

Country Status (4)

Country Link
EP (1) EP1910524A4 (de)
JP (1) JP2008546721A (de)
CA (1) CA2612644A1 (de)
WO (1) WO2006135968A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324237B2 (en) 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
JP2008546393A (ja) * 2005-06-21 2008-12-25 メドベット サイエンス ピーティーワイ． リミティッド スフィンゴシンキナーゼのシグナル伝達の調節
EP2166094A1 (de) 2008-09-23 2010-03-24 Ecole Normale Superieure De Lyon Verfahren zur Verlängerung der durch eine Ernährungseinschränkung ausgelösten gesundheitsfördernden Auswirkungen unter Verwendung eines Sphingosin-Kinasehemmers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085953A1 (en) * 2000-05-11 2001-11-15 Medvet Science Pty. Ltd. Sphingosine kinase and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085953A1 (en) * 2000-05-11 2001-11-15 Medvet Science Pty. Ltd. Sphingosine kinase and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LECLERCQ TAMARA M ET AL: "Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, no. 15, April 2008 (2008-04-01), pages 9606 - 9614, XP002510631, ISSN: 0021-9258 *
See also references of WO2006135968A1 *
XIA P ET AL: "Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 277, no. 10, 8 March 2002 (2002-03-08), pages 7996 - 8003, XP002992506, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2006135968A1 (en) 2006-12-28
JP2008546721A (ja) 2008-12-25
CA2612644A1 (en) 2006-12-28
EP1910524A1 (de) 2008-04-16

Similar Documents

Publication Publication Date Title
IL187881A0 (en) Sphingosine kinase inhibitors
ZA200806277B (en) Triazolopyridazines as tyrosine kinase modulators
IL191880A0 (en) Compounds having cytokine modulating properties
GB0522477D0 (en) Modulator
SG126860A1 (en) Surgical clip
GB0619530D0 (en) Signalling
IL190078A0 (en) Kinase inhibitors
IL187693A0 (en) Aminopyrimidines as kinase modulators
IL187686A0 (en) Aminopyrimidines as kinase modulators
IL187692A0 (en) Alkylquinoline and alkylquinazoline kinase modulators
EP1922003A4 (de) Fixierplatte
SI1943243T1 (sl) Inhibotorji kinaz
EP1928847A4 (de) Theramuteinmodulatoren
DK2392335T3 (en) Use of 24-norUDCA
EP1910524A4 (de) Modulation der sphingosinkinase-signalgebung
EP1910525A4 (de) Modulation der sphingosinkinase-signalgebung
ZA200800275B (en) Aminopyrimidines as kinase modulators
ZA200800274B (en) Aminopyrimidines as kinase modulators
GB0526515D0 (en) Modulation of signalling pathways
HK1115334A (en) Modulation of sphingosine kinase signalling
HK1115416A (en) Modulation of sphingosine kinase signalling
GB0525900D0 (en) Markers
ZA200804747B (en) Compounds having cytokine modulating properties
GB2462019B (en) Railway signalling lamp
HK1115415A (en) Modulation of egfr signalling by modulation of sphingosine kinase signalling

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: VADAS, MATHEW, ALEXANDER

Inventor name: PITSON, STUART, M.

Inventor name: LECLERCQ, TAMARA

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1115334

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20090227

17Q First examination report despatched

Effective date: 20090623

R17C First examination report despatched (corrected)

Effective date: 20090715

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100126